A.R.T. Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

A.R.T. Advisors’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-18,790	Closed	-$86K	–	1225
2019 Q4	$86K	Sell	18,790 -118,779	-86%	-$470K	﹤0.01%	1225
2019 Q3	$533K	Buy	137,569 +33,000	+32%	+$181K	0.03%	832
2019 Q2	$631K	Buy	+104,569	New	+$1,000K	0.04%	652
2018 Q4	–	Sell	-28,259	Closed	-$393K	–	1809
2018 Q3	$393K	Sell	28,259 -22,110	-44%	-$329K	0.02%	947
2018 Q2	$796K	Sell	50,369 -108,400	-68%	-$1.89M	0.03%	737
2018 Q1	$2.73M	Buy	158,769 +6,500	+4%	+$127K	0.11%	270
2017 Q4	$3.34M	Buy	152,269 +127,295	+510%	+$4.09M	0.15%	193
2017 Q3	$1.02M	Buy	+24,974	New	+$784K	0.05%	523
2015 Q1	–	Sell	-20,385	Closed	-$550K	–	1796
2014 Q4	$550K	Buy	+20,385	New	+$351K	0.02%	896

Other funds holding FPRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

A.R.T. Advisors's FPRX Position: Q1 2020 in Review

A.R.T. Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2020, closing a stake of 18,790 shares — an estimated $86K sold.

A.R.T. Advisors first reported a position in FPRX in Q4 2014 and held it in 9 quarters. The position peaked at $3.34M in Q4 2017. 87 funds tracked by Wall St. Rank hold FPRX as of Q1 2020.

A.R.T. Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 18,790 Five Prime Therapeutics, Inc. shares in Q1 2020, an estimated $86K.
A.R.T. Advisors first reported a position in Five Prime Therapeutics, Inc. in Q4 2014 and held it in 9 quarters.
A.R.T. Advisors's Five Prime Therapeutics, Inc. position peaked at $3.34M in Q4 2017.
87 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.